- Home
- NRDY vs SLS Comparison
NRDY vs SLS Comparison
Compare NRDY & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDY
- SLS
- Stock Information
- Founded
- NRDY 2007
- SLS 2012
- Country
- NRDY United States
- SLS United States
- Employees
- NRDY N/A
- SLS N/A
- Industry
- NRDY Computer Software: Prepackaged Software
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NRDY Technology
- SLS Health Care
- Exchange
- NRDY Nasdaq
- SLS Nasdaq
- Market Cap
- NRDY 206.0M
- SLS 169.6M
- IPO Year
- NRDY N/A
- SLS N/A
- Fundamental
- Price
- NRDY $1.57
- SLS $1.85
- Analyst Decision
- NRDY Hold
- SLS
- Analyst Count
- NRDY 8
- SLS 0
- Target Price
- NRDY $1.90
- SLS N/A
- AVG Volume (30 Days)
- NRDY 568.6K
- SLS 2.4M
- Earning Date
- NRDY 08-07-2025
- SLS 08-12-2025
- Dividend Yield
- NRDY N/A
- SLS N/A
- EPS Growth
- NRDY N/A
- SLS N/A
- EPS
- NRDY N/A
- SLS N/A
- Revenue
- NRDY $184,099,000.00
- SLS N/A
- Revenue This Year
- NRDY $4.60
- SLS N/A
- Revenue Next Year
- NRDY $9.97
- SLS N/A
- P/E Ratio
- NRDY N/A
- SLS N/A
- Revenue Growth
- NRDY N/A
- SLS N/A
- 52 Week Low
- NRDY $0.73
- SLS $0.77
- 52 Week High
- NRDY $2.18
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- NRDY 43.08
- SLS 62.52
- Support Level
- NRDY $1.51
- SLS $1.50
- Resistance Level
- NRDY $1.90
- SLS $1.73
- Average True Range (ATR)
- NRDY 0.08
- SLS 0.11
- MACD
- NRDY -0.02
- SLS 0.02
- Stochastic Oscillator
- NRDY 15.38
- SLS 100.00
About NRDY Nerdy Inc.
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its proprietary platform leverages technology, including artificial intelligence ("AI"), to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. The company provides learning experiences across numerous subjects and multiple formats, including one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. The company generates revenue by selling services to learners and institutions for one-on-one instruction and small group tutoring.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.